A look at the progress of treating pancreatic cancer over the past 20 years. Issue 3 (4th March 2018)

• Record Type: Journal Article
• Authors: Goess, Ruediger; Friess, Helmut
• Is Part Of: Expert review of anticancer therapy. Volume 18:Issue 3(2018)
• Page Start: 295
• Page End: 304
• Publication Date: 2018-03-04
• Subjects: Pancreatic cancer -- pancreatic cancer treatment -- pancreatic surgery -- advanced pancreatic cancer -- adjuvant treatment -- neoadjuvant therapy; Cancer -- Treatment -- Periodicals; 616.99406
• DOI: 10.1080/14737140.2018.1428093
• Languages: English
• ISSNs: 1473-7140

Abstract

ABSTRACT: Introduction : Pancreatic cancer is known to be the deadliest of all common cancers. Despite all efforts in pancreatic cancer treatment, the five-year survival rates at diagnosis over the past 20 years have only increased from 5% to 8%. Assuming that pancreatic cancer is going to become the second most frequent cause of cancer related death in the next 20 years, we are all encouraged to treat patients in clinical trials to gain improvements in this devastating disease. Areas covered : This review will provide a summary of pancreatic cancer treatment over the last 20 years, starting with the pivotal study in 1997 which showed the superiority of gemcitabine over 5-FU in advanced pancreatic cancer and is marked as the beginning of a new era in pancreatic cancer treatment. This review will also focus on improvements in different areas of treatment, including pancreatic surgery, adjuvant treatment, neoadjuvant therapy and palliative therapy. Expert commentary : The treatment of pancreatic cancer has changed substantially in the last 20 years compared to almost no improvements in the decades before. This provides hope that more effective treatment options will become available in the near future. Particularly, new concepts such as neoadjuvant therapy in resectable and borderline-resectable tumors may potentially shift treatment strategies.